Genzyme Belgium Genzyme Corporate Search Contact us
HealthcarePatients & FamiliesPractical Info
A disease with many faces
 
Healthcare Professionals
About Lysosomal Storage Disease
Gaucher
Fabry
MPS I
Disease Information
Management of MPS I Disease
Symptomatic or corrective management
Specific therapies
About AldurazymeŽ
AldurazymeŽ clinical trial summary
Reconstitution & Administration
Importance of Compliance
Summary of Product Characteristics
Medical Information Services
MPS I Registry
Practical Info
Request Materials
Pompe

 



 

Management of MPS I disease

Because of the multisystemic and heterogeneous nature of MPS I disease, patients should receive multidisciplinary attention, including consultation with specialists in this disorder as necessary.

Individual management decisions will largely depend upon a comprehensive and regular evaluation of the severity and progression of the disease in that patient. Early intervention may enhance the benefits of treatment.

Treatment of MPS I can be classed as general symptomatic or corrective treatment and therapy specifically targeted at the underlying cause.

 
Print

PRINT

Bookmark

BOOKMARK




01/01/2007: Low bone density in Gaucher disease improves with CerezymeŽ

01/05/2007: Treatment for Pompe disease now available for Belgian patients

01/03/2006: Early treatment with FabrazymeŽ significantly slows progression of Fabry

More >



Lysosomal Storage Disorders
General information
Gaucher Disease
Fabry Disease
MPS I Disease
Pompe Disease